Oncologists Lack Biosimilar Awareness

The Center for Biosimilars reports on a recent study highlighting a lack of biosimilar awareness among oncology doctors.  What follows is the Center for Biosimilar response to the study. The need for improved biosimilar education among providers has been an...

FDA Approves Coherus Pegfilgrastim Biosimilar Udencya

The biosimilar, referencing Neulasta, has been approved to decrease the incidence of infection, as manifested by febrile neutropenia, in patients receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia. “We are...

Pin It on Pinterest